CDK4 and melanoma: Furthermore, we demonstrated that pharmacological MAP3K3 inhibition can overcome YAP-induced resistance to CDK4/6 inhibitors in breast cancer cells and to BRAF inhibitors in melanoma cells, underscoring the therapeutic relevance of our findings.